PMID: 7032555Nov 1, 1981Paper

Effect of captopril on renal function in patients with congestive heart failure

British Heart Journal
G L PierpontJ N Cohn

Abstract

Angiotensin converting enzyme inhibitors can improve haemodynamics in patients with congestive heart failure and may enhance sodium excretion in hypertensive patients. In a metabolic unit we assessed the effects of one of these agents on renal function in nine patients with stable New York Heart Association functional class 3 or 4 congestive heart failure. Single blinded, the patients received placebo for three days, 25 to 100 mg of captopril three times a day for three days, and three more days of placebo. Mean blood pressure decreased during captopril, with little change in heart rate or respiration. Serum urea was slightly higher during captopril administration. The mean change in creatinine clearance during captopril was insignificant, but it decreased more than 25% in three of nine patients. Decreases in creatinine clearance correlated with lower blood pressure during captopril and were most obvious in patients with high baseline plasma renin activity. Urine output and both sodium and potassium excretion decreased during captopril. Thus captopril failed to improve natriuresis in patients with congestive heart failure and close monitoring of kidney function is necessary when using this agent in patients with congestive hear...Continue Reading

References

Jul 5, 1979·The New England Journal of Medicine·N K HollenbergG H Williams
Jun 7, 1980·Lancet·S J HoorntjeP J Hoedemaeker
Jun 19, 1980·The New England Journal of Medicine·V J DzauN K Hollenberg
Jul 25, 1980·JAMA : the Journal of the American Medical Association·D B CaseJ H Laragh

❮ Previous
Next ❯

Citations

Jan 1, 1984·European Journal of Clinical Pharmacology·Z GlückF C Reubi
Jan 1, 1987·Cardiovascular Drugs and Therapy·K Chatterjee, L H Opie
Jan 1, 1983·Journal of the American College of Cardiology·K Chatterjee, W W Parmley
Apr 1, 1983·British Heart Journal·H J DargieJ I Robertson
Dec 1, 1989·Cardiovascular Drugs and Therapy·J L RouleauJ de Champlain
Mar 1, 1992·The American Journal of the Medical Sciences·D Subramanian, J C Ayus
Jun 1, 1987·Kidney International·V J Dzau
Oct 1, 1984·The American Journal of Medicine·R K FergusonH H Rotmensch
Dec 1, 1988·The American Journal of Cardiology·M D MeissnerM Jessup
Jan 1, 1982·British Journal of Clinical Pharmacology·U Dahlström, B E Karlberg
Sep 9, 1988·The American Journal of Cardiology·N K Hollenberg
Apr 24, 1987·The American Journal of Cardiology·I G CrozierS Jans
Oct 2, 1990·The American Journal of Cardiology·S S Gottlieb, M R Weir
Sep 1, 1987·International Journal of Cardiology·A M ScammellJ L Wilkinson
Sep 1, 1990·Heart & Lung : the Journal of Critical Care·M Galvao
Aug 20, 1988·BMJ : British Medical Journal·J Dobbing
Aug 20, 1988·BMJ : British Medical Journal·R W Ellwood
Dec 7, 2007·Clinical Science·Miriam T RademakerA Mark Richards
May 1, 1990·DICP : the Annals of Pharmacotherapy·J J RaiaC R Lacy
Jan 1, 1986·Acta Medica Scandinavica. Supplementum·C Grönhagen-Riska
May 1, 1990·DICP : the Annals of Pharmacotherapy·N A Mason

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.